News
OGN
18.46
+0.22%
0.04
The Sound Shore Fund Q1 2024 Letter To Shareholders
The Sound Shore Fund Investor Class and Institutional Class advanced 17.05% and 17.10% in the first quarter of 2024. The Fund's strong first quarter 2024 gain was substantially ahead of both the Russell Value and S&P 500 indices. The fund's portfolio return was driven by 12 holdings from seven different sectors.
Seeking Alpha · 2d ago
Barclays Sticks to Their Buy Rating for Organon (OGN)
TipRanks · 3d ago
Weekly Report: what happened at OGN last week (0415-0419)?
Weekly Report · 4d ago
Little Excitement Around Organon & Co.'s (NYSE:OGN) Earnings
Organon & Co. (NYSE:OGN) has a low price-to-earnings ratio of 4.5x. The company is expected to grow earnings at a lower rate than the broader market. Its low P/E ratio is typical of a company expected to perform worse than the market. Organon's earnings growth has fallen 55% in the last three years. It might be a good idea to look for a better investment with a lower P/e.
Simply Wall St · 5d ago
Organon’s Steady Market Position Maintains Neutral Rating Amidst Conservative Revenue Forecasts
TipRanks · 04/19 05:45
CVS favors Humira copycats hurting AbbVie’s market share: Evercore
Seeking Alpha · 04/17 13:26
Should WisdomTree U.S. SmallCap Dividend ETF (DES) Be on Your Investing Radar?
NASDAQ · 04/16 10:20
Organon (OGN) Advances While Market Declines: Some Information for Investors
NASDAQ · 04/15 22:15
Weekly Report: what happened at OGN last week (0408-0412)?
Weekly Report · 04/15 09:08
AbbVie keeps Humira market share near 100% despite biosimilars: report
Healthcare AbbVie keeps Humira market share near 100% despite biosimilars: report. Humira is the world's bestselling drug for the 10th year in a row. Amgen launched the first biosimilar version of the arthritis drug in the U.S. Last year.
Seeking Alpha · 04/13 14:52
Molina (MOH) Wins Deal to Serve Michigan's Medicaid Members
NASDAQ · 04/12 16:37
Play Safe! S&P 500 is Teasingly Close to its 50 DMA: 3 Picks
NASDAQ · 04/12 12:09
ORGANON & CO. <OGN.N>: MORGAN STANLEY RAISES TARGET PRICE TO $18.00 FROM $17.00
Reuters · 04/10 14:48
Why HCA Healthcare (HCA) is a Smart Addition to Your Portfolio
NASDAQ · 04/09 18:24
Why the Market Dipped But Organon (OGN) Gained Today
NASDAQ · 04/08 22:15
PHASE 3 COMPARATIVE CLINICAL STUDY OF PROLIA® AND XGEVA® (DENOSUMAB) BIOSIMILAR CANDIDATE HLX14 MET PRIMARY ENDPOINTS
Reuters · 04/08 10:00
Weekly Report: what happened at OGN last week (0401-0405)?
Weekly Report · 04/08 09:09
Organon To Report First Quarter 2024 Results and Host Conference Call on May 2, 2024
Organon will release its first quarter 2024 financial results on May 2, 2024. The company expects to record approximately $15 million of milestone payments in the first quarter of 2024. Organon is a global healthcare company with a focus on women’s health. The live webcast and conference call will be available on the company's website.
Barchart · 04/08 05:15
Encompass Health (EHC) Plans a 50-Bed Facility to Serve Texas
NASDAQ · 04/04 17:37
Weekly Report: what happened at OGN last week (0325-0329)?
Weekly Report · 04/01 09:09
More
Webull provides a variety of real-time OGN stock news. You can receive the latest news about ORGANON & CO through multiple platforms. This information may help you make smarter investment decisions.
About OGN
Organon & Co. is a global health care company. The Company is engaged in developing and delivering health solutions through a portfolio of prescription therapies and medical devices within women's health, biosimilars and established brands. It has a portfolio of contraception and fertility brands, including Nexplanon, NuvaRing, and Follistim AQ. The Company’s Biosimilars portfolio spans across immunology and oncology treatments. It also has a portfolio of established brands, including brands in cardiovascular, respiratory, dermatology and non-opioid pain management. It sells these products through various channels, including drug wholesalers and retailers, hospitals, government agencies and managed health care providers, such as health maintenance organizations, pharmacy benefit managers and other institutions. The Company operates six manufacturing facilities, which are located in Belgium, Brazil, Indonesia, Mexico, the Netherlands and the United Kingdom.